Table 3

TEAEs of any grade observed in all patients

Event, n (%)	Cohort 1 (n=8)		Cohort 4 (n=10)		Total (n=18)
Event, n (%)	Grade 1–2	Grade 3–4	Grade 1–2	Grade 3–4	Grade 1–2	Grade 3–4	Any grade
Any TEAE	4 (50.0)	4 (50.0)	5 (50.0)	5 (50.0)	9 (50.9)	9 (50.0)	18 (100.0)
Nausea	4 (50.0)	0	2 (20.0)	0	6 (33.3)	0	6 (33.3)
Decreased appetite	3 (37.5)	1 (12.5)	1 (10.0)	1 (10.0)	4 (22.2)	2 (11.1)	6 (33.3)
Fatigue	2 (25.0)	1 (12.5)	2 (20.0)	1 (10.0)	4 (22.2)	2 (11.1)	6 (33.3)
Anemia	0	2 (25.0)	0	2 (20.0)	0	4 (22.2)	4 (22.2)
Fever	2 (25.0)	0	2 (20.0)	0	4 (22.2)	0	4 (22.2)
Malaise	3 (37.5)	0	1 (10.0)	0	4 (22.2)	0	4 (22.2)
Rash	1 (12.5)	0	3 (30.0)	0	4 (22.2)	0	4 (22.2)
Constipation	2 (25.0)	0	1 (10.0)	0	3 (16.7)	0	3 (16.7)
Diarrhea	1 (12.5)	0	2 (20.0)	0	3 (16.7)	0	3 (16.7)
Stomatitis	0	0	3 (30.0)	0	3 (16.7)	0	3 (16.7)
Cancer pain	1 (12.5)	0	1 (10.0)	1 (10.0)	2 (11.1)	1 (5.6)	3 (16.7)
Edema, peripheral	1 (12.5)	0	1 (10.0)	0	2 (11.1)	0	2 (11.1)
White blood cell count decreased	0	0	2 (20.0)	0	2 (11.1)	0	2 (11.1)
Neutrophil count decreased	0	0	1 (10.0)	1 (10.0)	1 (5.6)	1 (5.6)	2 (11.1)
Disseminated intravascular coagulation	0	0	0	1 (10.0)	0	1 (5.6)	1 (5.6)
Iron deficiency anemia	0	1 (12.5)	0	0	0	1 (5.6)	1 (5.6)
Hypothyroidism	0	0	1 (10.0)	0	1 (5.6)	0	1 (5.6)
Vomiting	1 (12.5)	0	0	0	1 (5.6)	0	1 (5.6)
General physical health deterioration	0	1 (12.5)	0	0	0	1 (5.6)	1 (5.6)
Cholangitis	0	0	0	1 (10.0)	0	1 (5.6)	1 (5.6)
Aspartate aminotransferase increased	0	0	0	1 (10.0)	0	1 (5.6)	1 (5.6)
Alanine aminotransferase increased	0	0	1 (10.0)	0	1 (5.6)	0	1 (5.6)
Hypoalbuminemia	0	0	1 (10.0)	0	1 (5.6)	0	1 (5.6)
Hypoglycemia	0	0	0	1 (10.0)	0	1 (5.6)	1 (5.6)
Peripheral sensory neuropathy	0	0	1 (10.0)	0	1 (5.6)	0	1 (5.6)
Headache	1 (12.5)	0	0	0	1 (5.6)	0	1 (5.6)
Hydronephrosis	0	1 (12.5)	0	0	0	1 (5.6)	1 (5.6)

TEAE, treatment-emergent adverse event.